A review of the “OMICS” for management of patients with obstructive sleep apnoea
Luana Conte(University of Salento), Michele De Benedetto(Ospedale Vito Fazzi), Michele Arigliani(Ospedale Vito Fazzi), Domenico Maurizio Toraldo(Ospedale Policlinico San Martino), Michele Maffia(University of Salento), Marco Greco(Hospital Clínico Universitario de Valencia)
Cited by 19
Related Papers
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
|Journal of Clinical Oncology|2009|216
Association between [ 18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation
|European Journal of Nuclear Medicine and Molecular Imaging|1998|186
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
|Clinical Cancer Research|2005|165
Targeting the gut–lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection
|Therapeutic Advances in Respiratory Disease|2020|95
Obstructive Sleep Apnea With or Without Excessive Daytime Sleepiness: Clinical and Experimental Data-Driven Phenotyping
|Frontiers in Neurology|2018|92